Patents
Literature
34results about How to "Less reversible" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Phenyl guanidine sodium channel blockers
InactiveUS6858615B2Increased mucociliary clearanceAbsorbed less rapidlyBiocideSenses disorderStructural variableGuanidine
The present invention relates to a compound represented by formula (I): in which at least one of R3 and R4 is a group represented by formula (A): where the structural variables are as defined herein. The compounds are useful for blocking sodium channels.
Owner:PARION SCI DURHAM NC
Phenolic guanidine sodium channel blockers
InactiveUS6858614B2Increased mucociliary clearanceAbsorbed less rapidlyBiocideSenses disorderGuanidineSodium channel blocker
The present invention relates to compounds represented by formula (I): in which at least one of R3 and R4 is a group represented by formula (A): where the structural variables are defined herein. The compounds are useful for blocking sodium channels.
Owner:PARION SCI DURHAM NC
Sodium channel blockers
InactiveUS6903105B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderTreatment useCalcium channel blocker
The present invention relates to pyrazinoylguanidine compounds represented by formula (I): where at least one of R3 and R4 is a group represented by formula (A): where the other structural groups are defined herein. The present invention also includes a variety of methods of treatment using these sodium channel blockers.
Owner:PARION SCI DURHAM NC
Sodium channel blockers
InactiveUS7192958B2More potent and/or absorbed less rapidlyLess reversibleBiocideSenses disorderChannel blockerCalcium channel blocker
The present invention relates to compounds represented by formula (I):in which at least one of R3 and R4 is a group represented by formula (A):where the structural variables are defined herein. The compounds are useful for blocking sodium channels.
Owner:PARION SCI DURHAM NC
Sodium channel blockers
InactiveUS7186833B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderOrganic chemistryMedicinal chemistry
Owner:PARION SCI DURHAM NC
Sodium channel blockers
InactiveUS7192959B2More potent and/or absorbed less rapidlyLess reversibleBiocideSenses disorderStructural variableStereochemistry
The present invention relates to compounds represented by formula (I):in which at least one of R3 and R4 is a group represented by formula (A):where the structural variables are defined herein. The compounds are useful for blocking sodium channels.
Owner:PARION SCI DURHAM NC
Cyclic pyrazinoylguanidine sodium channel blockers
ActiveUS7317013B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderChannel blockerStructural variable
The present invention provides sodium channel blockers represented by formula (I):where the structural variables are defined herein. The compounds of the present invention may be used for treating a variety of conditions as described herein.
Owner:PARION SCI DURHAM NC
Soluble amide & ester pyrazinoylguanidine sodium channel blockers
ActiveUS7399766B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsBiocideChannel blockerStructural variable
Owner:PARION SCI DURHAM NC
Alaphatic pyrazinoylguanidine sodium channel blockers
ActiveUS7375107B2More potent and/or absorbed less rapidlyLess reversibleBiocideOrganic active ingredientsDiseasePyrazine
The present invention provides compound represented by formula (I):where the structural variables are defined herein. The compounds function as sodium channel blockers and may be used to treat a variety of respiratory conditions.
Owner:PARION SCI DURHAM NC
Sodium channel blockers
InactiveUS20060142306A1More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderTreatment useChemistry
Owner:CYFI
Alaphatic pyrazinoylguanidine sodium channel blockers
ActiveUS20050080092A1Absorbed less rapidlyMore potentOrganic active ingredientsSenses disorderChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Aliphatic amide and ester pyrazinoylguanidine sodium channel blockers
InactiveUS7956059B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderCombinatorial chemistryChannel blocker
The present invention relates to pyrazinoylguanidine compounds represented by formula (I):where the structural variables are defined herein. The compounds are useful as, for example, sodium channel blockers.
Owner:PARION SCI DURHAM NC
Poly aromatic pyrazinoylguanidine sodium channel blockers
ActiveUS8124607B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Soluble amide & ester pyrazinoylguanidine sodium channel blockers
ActiveUS20060040954A1More potent and/or absorbed less rapidlyLess reversibleBiocideOrganic active ingredientsChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Cyclic amide and ester pyrazinoylguanidine sodium channel blockers
ActiveUS8143256B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderCombinatorial chemistryChannel blocker
The present invention provides compounds represented by formula (I):where the structural variables are defined herein. The compound of the present invention are useful as sodium channel blockers.
Owner:PARION SCI DURHAM NC
Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
InactiveUS8058278B2More specificAbsorbed less rapidlyAntibacterial agentsOrganic active ingredientsDiseaseOsmolyte
The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.
Owner:PARION SCI DURHAM NC
Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
ActiveUS8163758B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderDiseaseAgonist
Owner:PARION SCI DURHAM NC
New capped pyrazinoylguanidine sodium channel blockers
InactiveUS20070032509A1Less surfaceLess reversibleSenses disorderNervous disorderChemistryTreatment use
Owner:PARION SCI DURHAM NC
Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.
Owner:PARION SCI DURHAM NC
Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
ActiveUS8324218B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderDiseaseSinusitis
The present application provides sodium channel blockers exemplified by the following structure:The compounds of the invention useful for treating chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, Sjogren's disease, distal intestinal obstruction syndrome, dry skin, esophagitis, dry mouth (xerostomia), nasal dehydration, ventilator-induced pneumonia, asthma, primary ciliary dyskinesia, otitis media, chronic obstructive pulmonary disease, emphysema, pneumonia, constipation, and chronic diverticulitis, for example.
Owner:PARION SCI DURHAM NC
Capped pyrazinoylguanidine sodium channel blockers
ActiveUS20050228182A1More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Soluble amide & ester pyrazinoylguanidine sodium channel blockers
InactiveUS20090324724A1More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsPowder deliveryChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Sodium channel blockers
InactiveUS20050113390A1More potentLess reversibleOrganic active ingredientsSenses disorderChemistryTreatment use
Owner:PARION SCI DURHAM NC
Sodium channel blockers
InactiveUS20050113389A1More potentLess reversibleOrganic active ingredientsSenses disorderChemistryTreatment use
Owner:PARION SCI DURHAM NC
Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.
Owner:PARION SCI DURHAM NC
Capped pyrazinoylguanidine sodium channel blockers
ActiveUS20050080091A1Increased mucociliary clearanceAbsorbed less rapidlyBiocideSenses disorderChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
InactiveUS20130324559A1More potentLess reversibleOrganic active ingredientsSenses disorderAmino amideSodium channel blocker
Owner:PARION SCI DURHAM NC
Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
ActiveUS20140142118A1Absorbed less rapidlyMore potent in vivoOrganic active ingredientsPeptidesDipeptideOrganic chemistry
A very stable, selective and renally safe sodium channel blocker represented by the formula: The invention also includes a variety of compositions, combinations and methods of treatment using this inventive sodium channel blocker.
Owner:PARION SCI DURHAM NC
Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
InactiveUS8980898B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderDendrimerDisease
Owner:PARION SCI DURHAM NC
PatSnap Eureka turns technology decisions into work you can execute. Powered by our Innovation Knowledge Graph, it runs expert workflows across engineering, life sciences, materials and intellectual property. Get your review-ready output in minutes.
